Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in March - Earnings Summary

Sonnet Biotherapeutics Holdings

10/05/2023 13:42

* Sonnet Biotherapeutics Holdings Inc  SONN.OQ  reported a
quarterly adjusted loss of 34 cents​​ per share for the quarter
ended in March. The mean expectation of two analysts for the
quarter was for a loss of 49 cents per share.
    * Revenue fell 61.8% to $36.45 thousand from a year ago;
analysts
expected zero. 
    * Sonnet Biotherapeutics Holdings Inc's reported EPS for the
quarter was a loss of 34 cents​.
    * The mean earnings estimate of analysts had risen by
about 13.2%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Sonnet Biotherapeutics Holdings Inc shares had fallen
by 33.9%
this quarter and lost 79.3% so far this year.
    * Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $11.85 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 12:42 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.49          -0.34          Beat
 Dec. 31 2022      -1.10          -0.80          Beat
 Sep. 30 2022      -1.51          -1.67          Missed
 Jun. 30 2022      -1.96          -1.82          Beat